Released Nov 7, 2016, after the close
10-Q filed Nov 7, 2016, 38 days after period end · 0001564590-16-027939
Q3 2016 · 10-Q
Revenue$1.03M$1.03M ±0.0% vs Q3 2015−0.1% vs Q2 2016
Net Income-$8.74M-$8.74M N/M vs Q3 2015N/M vs Q2 2016
EPS Diluted-$0.27-$0.27 N/M vs Q3 2015N/M vs Q2 2016
Operating Income-$8,389,000N/M
Operating Cash Flowderived-$7,516,000N/M
Free Cash Flowderived-$7,549,000N/M
Margins · derived
Operating margin-817.6%−200.9 pt vs Q3 2015
Net margin-851.6%−180.4 pt vs Q3 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2016 | Q3 2015 | Q3 2014 | Q3 2013 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | — | $209.00K |
| Net Income | -$8.74M | -$6.89M | -$6.60M | -$6.07M |
| EPS Diluted | -$0.27 | -$0.24 | -$0.32 | -$4.81 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR